Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
The purpose of this study is to confirm and extend the Phase 1-2 KB001 findings of an airway anti-inflammatory effect in CF individuals with chronic Pseudomonas aeruginosa (Pa) airway infection. It is hypothesized that steady-state levels of KB001-A in CF subjects with airway Pa infection will be safe and well-tolerated, and will increase the time-to-need for antibiotic treatment (IV, inhaled, or oral) for worsening of respiratory tract signs and symptoms compared with placebo.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Placebo Comparator
- biological: KB001-A
Eligibility
Inclusion Criteria:
- Individuals with CF who are older than 50 years of age may participate if treated with
2 or more courses of antibiotics (IV and/or oral) for respiratory sign and symptoms
(CF exacerbation) in the 12 months before the Screening Visit
- Confirmed diagnosis of CF
- At least 2 respiratory tract cultures in the previous 12 months, with Pa present. The
most recent positive Pa culture must be within 12 weeks before the Screening Visit (or
obtain a positive culture at screening)
- FEV1 % levels within acceptable ranges (per the study protocol)
- Received inhaled ABX for equivalent of 8 weeks or greater in the 26 weeks before the
Day 0 Visit
Exclusion Criteria:
- Treatment with antibiotics for acute illness within the 4 weeks before the Day 0 Visit
- Use of systemic corticosteroids within the 4 weeks before the Day 0 Visit
- Any change in regimen of CF maintenance therapies within the 4 weeks before the Day 0
Visit
- History of sputum cultures positive for B. cepacia complex in the 2 years before the
Screening Visit
- History of organ transplantation
- Current smoker (tobacco, marijuana, or any other material). Use of smokeless
inhalers/vaporizers for these materials is also prohibited
- History of drug addiction or alcohol abuse in the 12 months before the Screening Visit
- History of hepatic disease (clinical cirrhosis or portal hypertension), renal
dysfunction
- Breast-feeding or pregnancy as evidenced by a positive blood pregnancy test
- Receiving any investigational drug in the 16 weeks (or 5 half lives) before the Day 0
Visit, whichever is longer
Ages Eligible for Study
12 Years - 50 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Carlos Milla
650) 723-8325, (650) 736-9824
I'm interested
Psoriasis Clinical Trials
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
The purpose of this study is to confirm and extend the Phase 1-2 KB001 findings of an airway anti-inflammatory effect in CF individuals with chronic Pseudomonas aeruginosa (Pa) airway infection. It is hypothesized that steady-state levels of KB001-A in CF subjects with airway Pa infection will be safe and well-tolerated, and will increase the time-to-need for antibiotic treatment (IV, inhaled, or oral) for worsening of respiratory tract signs and symptoms compared with placebo.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Placebo Comparator
- biological: KB001-A
Eligibility
Inclusion Criteria:
- Individuals with CF who are older than 50 years of age may participate if treated with
2 or more courses of antibiotics (IV and/or oral) for respiratory sign and symptoms
(CF exacerbation) in the 12 months before the Screening Visit
- Confirmed diagnosis of CF
- At least 2 respiratory tract cultures in the previous 12 months, with Pa present. The
most recent positive Pa culture must be within 12 weeks before the Screening Visit (or
obtain a positive culture at screening)
- FEV1 % levels within acceptable ranges (per the study protocol)
- Received inhaled ABX for equivalent of 8 weeks or greater in the 26 weeks before the
Day 0 Visit
Exclusion Criteria:
- Treatment with antibiotics for acute illness within the 4 weeks before the Day 0 Visit
- Use of systemic corticosteroids within the 4 weeks before the Day 0 Visit
- Any change in regimen of CF maintenance therapies within the 4 weeks before the Day 0
Visit
- History of sputum cultures positive for B. cepacia complex in the 2 years before the
Screening Visit
- History of organ transplantation
- Current smoker (tobacco, marijuana, or any other material). Use of smokeless
inhalers/vaporizers for these materials is also prohibited
- History of drug addiction or alcohol abuse in the 12 months before the Screening Visit
- History of hepatic disease (clinical cirrhosis or portal hypertension), renal
dysfunction
- Breast-feeding or pregnancy as evidenced by a positive blood pregnancy test
- Receiving any investigational drug in the 16 weeks (or 5 half lives) before the Day 0
Visit, whichever is longer
Ages Eligible for Study
12 Years - 50 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Carlos Milla
650) 723-8325, (650) 736-9824
I'm interested
Dermatology Clinical Trials
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
The purpose of this study is to confirm and extend the Phase 1-2 KB001 findings of an airway anti-inflammatory effect in CF individuals with chronic Pseudomonas aeruginosa (Pa) airway infection. It is hypothesized that steady-state levels of KB001-A in CF subjects with airway Pa infection will be safe and well-tolerated, and will increase the time-to-need for antibiotic treatment (IV, inhaled, or oral) for worsening of respiratory tract signs and symptoms compared with placebo.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Placebo Comparator
- biological: KB001-A
Eligibility
Inclusion Criteria:
- Individuals with CF who are older than 50 years of age may participate if treated with
2 or more courses of antibiotics (IV and/or oral) for respiratory sign and symptoms
(CF exacerbation) in the 12 months before the Screening Visit
- Confirmed diagnosis of CF
- At least 2 respiratory tract cultures in the previous 12 months, with Pa present. The
most recent positive Pa culture must be within 12 weeks before the Screening Visit (or
obtain a positive culture at screening)
- FEV1 % levels within acceptable ranges (per the study protocol)
- Received inhaled ABX for equivalent of 8 weeks or greater in the 26 weeks before the
Day 0 Visit
Exclusion Criteria:
- Treatment with antibiotics for acute illness within the 4 weeks before the Day 0 Visit
- Use of systemic corticosteroids within the 4 weeks before the Day 0 Visit
- Any change in regimen of CF maintenance therapies within the 4 weeks before the Day 0
Visit
- History of sputum cultures positive for B. cepacia complex in the 2 years before the
Screening Visit
- History of organ transplantation
- Current smoker (tobacco, marijuana, or any other material). Use of smokeless
inhalers/vaporizers for these materials is also prohibited
- History of drug addiction or alcohol abuse in the 12 months before the Screening Visit
- History of hepatic disease (clinical cirrhosis or portal hypertension), renal
dysfunction
- Breast-feeding or pregnancy as evidenced by a positive blood pregnancy test
- Receiving any investigational drug in the 16 weeks (or 5 half lives) before the Day 0
Visit, whichever is longer
Ages Eligible for Study
12 Years - 50 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Carlos Milla
650) 723-8325, (650) 736-9824
I'm interested
Pediatric Dermatology Clinical Trials
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
The purpose of this study is to confirm and extend the Phase 1-2 KB001 findings of an airway anti-inflammatory effect in CF individuals with chronic Pseudomonas aeruginosa (Pa) airway infection. It is hypothesized that steady-state levels of KB001-A in CF subjects with airway Pa infection will be safe and well-tolerated, and will increase the time-to-need for antibiotic treatment (IV, inhaled, or oral) for worsening of respiratory tract signs and symptoms compared with placebo.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Placebo Comparator
- biological: KB001-A
Eligibility
Inclusion Criteria:
- Individuals with CF who are older than 50 years of age may participate if treated with
2 or more courses of antibiotics (IV and/or oral) for respiratory sign and symptoms
(CF exacerbation) in the 12 months before the Screening Visit
- Confirmed diagnosis of CF
- At least 2 respiratory tract cultures in the previous 12 months, with Pa present. The
most recent positive Pa culture must be within 12 weeks before the Screening Visit (or
obtain a positive culture at screening)
- FEV1 % levels within acceptable ranges (per the study protocol)
- Received inhaled ABX for equivalent of 8 weeks or greater in the 26 weeks before the
Day 0 Visit
Exclusion Criteria:
- Treatment with antibiotics for acute illness within the 4 weeks before the Day 0 Visit
- Use of systemic corticosteroids within the 4 weeks before the Day 0 Visit
- Any change in regimen of CF maintenance therapies within the 4 weeks before the Day 0
Visit
- History of sputum cultures positive for B. cepacia complex in the 2 years before the
Screening Visit
- History of organ transplantation
- Current smoker (tobacco, marijuana, or any other material). Use of smokeless
inhalers/vaporizers for these materials is also prohibited
- History of drug addiction or alcohol abuse in the 12 months before the Screening Visit
- History of hepatic disease (clinical cirrhosis or portal hypertension), renal
dysfunction
- Breast-feeding or pregnancy as evidenced by a positive blood pregnancy test
- Receiving any investigational drug in the 16 weeks (or 5 half lives) before the Day 0
Visit, whichever is longer
Ages Eligible for Study
12 Years - 50 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Carlos Milla
650) 723-8325, (650) 736-9824
I'm interested
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
The purpose of this study is to confirm and extend the Phase 1-2 KB001 findings of an airway anti-inflammatory effect in CF individuals with chronic Pseudomonas aeruginosa (Pa) airway infection. It is hypothesized that steady-state levels of KB001-A in CF subjects with airway Pa infection will be safe and well-tolerated, and will increase the time-to-need for antibiotic treatment (IV, inhaled, or oral) for worsening of respiratory tract signs and symptoms compared with placebo.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Placebo Comparator
- biological: KB001-A
Eligibility
Inclusion Criteria:
- Individuals with CF who are older than 50 years of age may participate if treated with
2 or more courses of antibiotics (IV and/or oral) for respiratory sign and symptoms
(CF exacerbation) in the 12 months before the Screening Visit
- Confirmed diagnosis of CF
- At least 2 respiratory tract cultures in the previous 12 months, with Pa present. The
most recent positive Pa culture must be within 12 weeks before the Screening Visit (or
obtain a positive culture at screening)
- FEV1 % levels within acceptable ranges (per the study protocol)
- Received inhaled ABX for equivalent of 8 weeks or greater in the 26 weeks before the
Day 0 Visit
Exclusion Criteria:
- Treatment with antibiotics for acute illness within the 4 weeks before the Day 0 Visit
- Use of systemic corticosteroids within the 4 weeks before the Day 0 Visit
- Any change in regimen of CF maintenance therapies within the 4 weeks before the Day 0
Visit
- History of sputum cultures positive for B. cepacia complex in the 2 years before the
Screening Visit
- History of organ transplantation
- Current smoker (tobacco, marijuana, or any other material). Use of smokeless
inhalers/vaporizers for these materials is also prohibited
- History of drug addiction or alcohol abuse in the 12 months before the Screening Visit
- History of hepatic disease (clinical cirrhosis or portal hypertension), renal
dysfunction
- Breast-feeding or pregnancy as evidenced by a positive blood pregnancy test
- Receiving any investigational drug in the 16 weeks (or 5 half lives) before the Day 0
Visit, whichever is longer
Ages Eligible for Study
12 Years - 50 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Carlos Milla
650) 723-8325, (650) 736-9824
I'm interested
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
The purpose of this study is to confirm and extend the Phase 1-2 KB001 findings of an airway anti-inflammatory effect in CF individuals with chronic Pseudomonas aeruginosa (Pa) airway infection. It is hypothesized that steady-state levels of KB001-A in CF subjects with airway Pa infection will be safe and well-tolerated, and will increase the time-to-need for antibiotic treatment (IV, inhaled, or oral) for worsening of respiratory tract signs and symptoms compared with placebo.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Placebo Comparator
- biological: KB001-A
Eligibility
Inclusion Criteria:
- Individuals with CF who are older than 50 years of age may participate if treated with
2 or more courses of antibiotics (IV and/or oral) for respiratory sign and symptoms
(CF exacerbation) in the 12 months before the Screening Visit
- Confirmed diagnosis of CF
- At least 2 respiratory tract cultures in the previous 12 months, with Pa present. The
most recent positive Pa culture must be within 12 weeks before the Screening Visit (or
obtain a positive culture at screening)
- FEV1 % levels within acceptable ranges (per the study protocol)
- Received inhaled ABX for equivalent of 8 weeks or greater in the 26 weeks before the
Day 0 Visit
Exclusion Criteria:
- Treatment with antibiotics for acute illness within the 4 weeks before the Day 0 Visit
- Use of systemic corticosteroids within the 4 weeks before the Day 0 Visit
- Any change in regimen of CF maintenance therapies within the 4 weeks before the Day 0
Visit
- History of sputum cultures positive for B. cepacia complex in the 2 years before the
Screening Visit
- History of organ transplantation
- Current smoker (tobacco, marijuana, or any other material). Use of smokeless
inhalers/vaporizers for these materials is also prohibited
- History of drug addiction or alcohol abuse in the 12 months before the Screening Visit
- History of hepatic disease (clinical cirrhosis or portal hypertension), renal
dysfunction
- Breast-feeding or pregnancy as evidenced by a positive blood pregnancy test
- Receiving any investigational drug in the 16 weeks (or 5 half lives) before the Day 0
Visit, whichever is longer
Ages Eligible for Study
12 Years - 50 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Carlos Milla
650) 723-8325, (650) 736-9824
I'm interested